DNA repair pathways and their therapeutic potential in lung cancer
暂无分享,去创建一个
Benjamin Solomon | Derek J. Richard | K. O'Byrne | B. Solomon | D. Richard | M. Adams | N. Wallace | J. Burgess | Mark N. Adams | Joshua T. Burgess | Kenneth J. O'Byrne | Sally-Anne Stephenson | S. Stephenson | Laura V. Croft | Nathan C Wallace | Nicholas W. Ashton | L. Croft | Sally A Stephenson | Nathan Wallace
[1] G. Pfeifer,et al. Mutational spectra of human cancer , 2009, Human Genetics.
[2] J. Holthuis. Etoposide and teniposide , 1988, Pharmaceutisch Weekblad.
[3] P. Hsieh,et al. DNA mismatch repair: Molecular mechanism, cancer, and ageing , 2008, Mechanisms of Ageing and Development.
[4] Jong Y. Park,et al. The human 8-oxoguanine DNA N-glycosylase 1 (hOGG1) DNA repair enzyme and its association with lung cancer risk. , 2004, Pharmacogenetics.
[5] D. Bau,et al. Lung cancer susceptibility and genetic polymorphisms of Exo1 gene in Taiwan. , 2009, Anticancer research.
[6] K. Osawa,et al. MUTYH Gln324His gene polymorphism and genetic susceptibility for lung cancer in a Japanese population , 2009, Journal of experimental & clinical cancer research : CR.
[7] D. Campa,et al. Polymorphisms of DNA repair genes and risk of non-small cell lung cancer. , 2006, Carcinogenesis.
[8] T. Eisen,et al. Genetic variation in the DNA repair genes is predictive of outcome in lung cancer. , 2007, Human molecular genetics.
[9] E. Felip,et al. BRCA1 mRNA expression levels as an indicator of chemoresistance in lung cancer. , 2004, Human molecular genetics.
[10] J. Pascal,et al. PARP-1 mechanism for coupling DNA damage detection to poly(ADP-ribose) synthesis. , 2013, Current opinion in structural biology.
[11] N. Tretyakova,et al. Tobacco smoke carcinogens, DNA damage and p53 mutations in smoking-associated cancers , 2002, Oncogene.
[12] N. Rothman,et al. Polymorphisms in the DNA base excision repair genes APEX1 and XRCC1 and lung cancer risk in Xuan Wei, China. , 2005, Anticancer research.
[13] J. Luketich,et al. Polymorphisms in DNA repair genes XPD and XRCC1 and p53 mutations in lung carcinomas of never‐smokers , 2006, Molecular carcinogenesis.
[14] Y. Miyoshi,et al. Decreased expression of BRCA2 mRNA predicts favorable response to docetaxel in breast cancer , 2001, International journal of cancer.
[15] S. Carr,et al. Mammalian Chk2 is a downstream effector of the ATM-dependent DNA damage checkpoint pathway , 1999, Oncogene.
[16] A. D’Andrea,et al. DNA repair pathways in clinical practice: lessons from pediatric cancer susceptibility syndromes. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[17] B. Hang. Formation and Repair of Tobacco Carcinogen-Derived Bulky DNA Adducts , 2010, Journal of nucleic acids.
[18] J. Bartek,et al. The DNA-damage response in human biology and disease , 2009, Nature.
[19] M. Lieber,et al. The mechanism of double-strand DNA break repair by the nonhomologous DNA end-joining pathway. , 2010, Annual review of biochemistry.
[20] J. Minna,et al. The 630-kb lung cancer homozygous deletion region on human chromosome 3p21.3: identification and evaluation of the resident candidate tumor suppressor genes. The International Lung Cancer Chromosome 3p21.3 Tumor Suppressor Gene Consortium. , 2000, Cancer research.
[21] Stephen H. Friend,et al. Potential of the Synthetic Lethality Principle , 2013, Science.
[22] J. Minna,et al. Sequential molecular abnormalities are involved in the multistage development of squamous cell lung carcinoma , 1999, Oncogene.
[23] A. Fornace,et al. Deletion of XPC leads to lung tumors in mice and is associated with early events in human lung carcinogenesis. , 2005, Proceedings of the National Academy of Sciences of the United States of America.
[24] Zhihui Feng,et al. A dual role of BRCA1 in two distinct homologous recombination mediated repair in response to replication arrest , 2011, Nucleic acids research.
[25] J Zhang,et al. High-Level mRNA of Excision Repair Cross-Complementation Group 1 Gene Is Associated With Poor Outcome of Platinum-Based Doublet Chemotherapy of Advanced Nonsmall Cell Lung Cancer Patients , 2010, Cancer investigation.
[26] A. Rossi,et al. The potential role of new targeted therapies in the treatment of advanced non-small-cell lung cancer , 2013 .
[27] M. Gottesman,et al. Multidrug resistance in cancer: role of ATP–dependent transporters , 2002, Nature Reviews Cancer.
[28] P. Ellis,et al. ABT-888 Confers Broad In vivo Activity in Combination with Temozolomide in Diverse Tumors , 2009, Clinical Cancer Research.
[29] Association between the OGG1 Ser326Cys and APEX1 Asp148Glu polymorphisms and lung cancer risk: a meta-analysis , 2012, Molecular Biology Reports.
[30] E. Liu,et al. BRCA1 and GADD45 mediated G2/M cell cycle arrest in response to antimicrotubule agents , 2001, Oncogene.
[31] Scott H. Kaufmann,et al. Failure of Iniparib to Inhibit Poly(ADP-Ribose) Polymerase In Vitro , 2012, Clinical Cancer Research.
[32] J. Minna,et al. 3p21.3 tumor suppressor cluster: prospects for translational applications. , 2005, Future oncology.
[33] E. Birney,et al. Patterns of somatic mutation in human cancer genomes , 2007, Nature.
[34] Wei Wu,et al. Association between polymorphisms in XRCC1 gene and clinical outcomes of patients with lung cancer: a meta-analysis , 2012, BMC Cancer.
[35] S. Johnson,et al. Increased nucleotide excision repair in cisplatin-resistant ovarian cancer cells: role of ERCC1-XPF. , 2000, Biochemical pharmacology.
[36] D. Spigel. PARP inhibitors in lung cancer. , 2012, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.
[37] J. Minna,et al. p53: a frequent target for genetic abnormalities in lung cancer. , 1989, Science.
[38] Zhefu Ma,et al. MDC1 interacts with Rad51 and facilitates homologous recombination , 2005, Nature Structural &Molecular Biology.
[39] Renato Martins,et al. Non-small cell lung cancer, version 2.2013: Featured updates to the NCCN guidelines , 2013 .
[40] Krishna R. Kalari,et al. Genetic association with overall survival of taxane-treated lung cancer patients - a genome-wide association study in human lymphoblastoid cell lines followed by a clinical association study , 2012, BMC Cancer.
[41] I. Demuth,et al. Expression pattern of the Nijmegen breakage syndrome gene, Nbs1, during murine development. , 2000, Human molecular genetics.
[42] T. Hamilton,et al. Platinum Resistance: The Role of DNA Repair Pathways , 2008, Clinical Cancer Research.
[43] P. Musiani,et al. Role of MUTYH and MSH2 in the control of oxidative DNA damage, genetic instability, and tumorigenesis. , 2009, Cancer research.
[44] J. McLaughlin,et al. Meta-analyses of p53 tumor suppressor gene alterations and clinicopathological features in resected lung cancers. , 1999, Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology.
[45] T. Halazonetis,et al. Genomic instability — an evolving hallmark of cancer , 2010, Nature Reviews Molecular Cell Biology.
[46] L. Le Marchand,et al. Association of the hOGG1 Ser326Cys polymorphism with lung cancer risk. , 2002, Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology.
[47] Hong Wei,et al. Expression of the Mismatch Repair Gene hMLH1 Is Enhanced in Non-Small Cell Lung Cancer with EGFR Mutations , 2013, PloS one.
[48] U. Vogel,et al. No Association Between Base Excision Repair Gene Polymorphisms and Risk of Lung Cancer , 2004, Biochemical Genetics.
[49] Mark Yoffe,et al. Iniparib plus chemotherapy in metastatic triple-negative breast cancer. , 2011, The New England journal of medicine.
[50] D. Mavroudis,et al. ERCC1 and BRAC1 mRNA Expression Levels in the Primary Tumor Could Predict the Effectiveness of the Second-Line Cisplatin-Based Chemotherapy in Pretreated Patients with Metastatic Non-small Cell Lung Cancer , 2012, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.
[51] A. Rossi,et al. Treatment of patients with small-cell lung cancer: from meta-analyses to clinical practice. , 2013, Cancer treatment reviews.
[52] Jun Yokota,et al. Molecular processes of chromosome 9p21 deletions in human cancers , 2003, Oncogene.
[53] K. Dahm. Functions and regulation of human artemis in double strand break repair , 2007, Journal of cellular biochemistry.
[54] Michael M. Murphy,et al. ATM Phosphorylates Histone H2AX in Response to DNA Double-strand Breaks* , 2001, The Journal of Biological Chemistry.
[55] Christian Ruiz,et al. Advancing a clinically relevant perspective of the clonal nature of cancer , 2011, Proceedings of the National Academy of Sciences.
[56] D. Matei,et al. Olaparib maintenance therapy in platinum-sensitive relapsed ovarian cancer. , 2012, The New England journal of medicine.
[57] H. Wang,et al. Significant association of DNA repair gene Ku80 genotypes with breast cancer susceptibility in Taiwan. , 2009, Anticancer research.
[58] L. Dai,et al. XRCC1 gene polymorphisms and lung cancer susceptibility: a meta-analysis of 44 case–control studies , 2012, Molecular Biology Reports.
[59] Yun-Chul Hong,et al. Genetic polymorphisms of ataxia telangiectasia mutated affect lung cancer risk. , 2006, Human molecular genetics.
[60] G. Garinis,et al. Nucleotide excision repair: new tricks with old bricks. , 2012, Trends in genetics : TIG.
[61] M. Spitz,et al. ATM sequence variants associate with susceptibility to non‐small cell lung cancer , 2007, International journal of cancer.
[62] Wei Chen,et al. Multi‐loci analysis reveals the importance of genetic variations in sensitivity of platinum‐based chemotherapy in non‐small‐cell lung cancer , 2013, Molecular carcinogenesis.
[63] N. Bowden. Nucleotide excision repair: why is it not used to predict response to platinum-based chemotherapy? , 2014, Cancer letters.
[64] Stephen S Hecht,et al. Lung carcinogenesis by tobacco smoke , 2012, International journal of cancer.
[65] Takako Noguchi,et al. Tip60 Is Regulated by Circadian Transcription Factor Clock and Is Involved in Cisplatin Resistance* , 2008, Journal of Biological Chemistry.
[66] APE1 Asp148Glu gene polymorphism and bladder cancer risk: a meta-analysis , 2011, Molecular Biology Reports.
[67] K. O'Byrne,et al. Oxidative stress induced lung cancer and COPD: opportunities for epigenetic therapy , 2009, Journal of cellular and molecular medicine.
[68] Shunichi Takeda,et al. Single-stranded DNA-binding protein hSSB1 is critical for genomic stability , 2008, Nature.
[69] M. Lieber,et al. Roles of nonhomologous DNA end joining, V(D)J recombination, and class switch recombination in chromosomal translocations. , 2006, DNA repair.
[70] Michael M Gottesman,et al. Cisplatin Resistance: A Cellular Self-Defense Mechanism Resulting from Multiple Epigenetic and Genetic Changes , 2012, Pharmacological Reviews.
[71] D. Quinlan,et al. Accumulation of p53 protein correlates with a poor prognosis in human lung cancer. , 1992, Cancer research.
[72] Beatriz Bellosillo,et al. Diversity of genomic breakpoints in TFG-ALK translocations in anaplastic large cell lymphomas: identification of a new TFG-ALK(XL) chimeric gene with transforming activity. , 2002, The American journal of pathology.
[73] Kum Kum Khanna,et al. Recent Advances in Cancer Therapy Targeting Proteins Involved in DNA Double-Strand Break Repair , 2009, Clinical Cancer Research.
[74] H. Aburatani,et al. Identification of the transforming EML4–ALK fusion gene in non-small-cell lung cancer , 2007, Nature.
[75] M. Spitz,et al. Prognostic significance of ataxia‐telangiectasia mutated, DNA‐dependent protein kinase catalytic subunit, and Ku heterodimeric regulatory complex 86‐kD subunit expression in patients with nonsmall cell lung cancer , 2008, Cancer.
[76] A. Ashworth,et al. The DNA damage response and cancer therapy , 2012, Nature.
[77] Limin Wang,et al. Ku80 is differentially expressed in human lung carcinomas and upregulated in response to irradiation in mice. , 2011, DNA and cell biology.
[78] Robert W Sobol,et al. Base excision repair and lesion-dependent subpathways for repair of oxidative DNA damage. , 2011, Antioxidants & redox signaling.
[79] Roger A. Jones,et al. Formation of diastereomeric benzo[a]pyrene diol epoxide-guanine adducts in p53 gene-derived DNA sequences. , 2004, Chemical research in toxicology.
[80] Dong Wang,et al. APE1 overexpression is associated with cisplatin resistance in non-small cell lung cancer and targeted inhibition of APE1 enhances the activity of cisplatin in A549 cells. , 2009, Lung cancer.
[81] Association between the NBS1 Glu185Gln polymorphism and lung cancer risk: a systemic review and meta-analysis , 2013, Molecular Biology Reports.
[82] M. Gallucci,et al. Tumor specific modulation of KU70/80 DNA binding activity in breast and bladder human tumor biopsies , 2001, Oncogene.
[83] Carlos Caldas,et al. The implications of clonal genome evolution for cancer medicine. , 2013, The New England journal of medicine.
[84] D. Butkiewicz,et al. Influence of DNA repair gene polymorphisms on prognosis in inoperable non‐small cell lung cancer patients treated with radiotherapy and platinum‐based chemotherapy , 2012, International journal of cancer.
[85] Seungbok Lee,et al. A transforming KIF5B and RET gene fusion in lung adenocarcinoma revealed from whole-genome and transcriptome sequencing. , 2012, Genome research.
[86] M. Weitzman,et al. The MRN complex in double‐strand break repair and telomere maintenance , 2010, FEBS letters.
[87] J. Bujnicki,et al. Databases and Bioinformatics Tools for the Study of DNA Repair , 2011, Molecular biology international.
[88] J. Kobayashi,et al. Molecular mechanism of the recruitment of NBS1/hMRE11/hRAD50 complex to DNA double-strand breaks: NBS1 binds to gamma-H2AX through FHA/BRCT domain. , 2004, Journal of radiation research.
[89] R. Sobti,et al. Contrasting impact of DNA repair gene XRCC1 polymorphisms Arg399Gln and Arg194Trp on the risk of lung cancer in the north-Indian population. , 2007, DNA and cell biology.
[90] Yunmei Ma,et al. Hairpin Opening and Overhang Processing by an Artemis/DNA-Dependent Protein Kinase Complex in Nonhomologous End Joining and V(D)J Recombination , 2002, Cell.
[91] H. van Steeg,et al. Oxidative DNA damage and nucleotide excision repair. , 2013, Antioxidants & redox signaling.
[92] M. Fiegl,et al. Prognostic and Predictive Value of Cell Cycle Deregulation in Non-Small-Cell Lung Cancer , 2012, Pathobiology.
[93] Li Wang,et al. MK-4827, a PARP-1/-2 inhibitor, strongly enhances response of human lung and breast cancer xenografts to radiation , 2012, Investigational New Drugs.
[94] Fengli Wang,et al. The role of PARP1 in the DNA damage response and its application in tumor therapy , 2012, Frontiers of Medicine.
[95] L. Mullenders,et al. The role of XPC: implications in cancer and oxidative DNA damage. , 2011, Mutation research.
[96] K. O'Byrne,et al. Generation and Characterisation of Cisplatin-Resistant Non-Small Cell Lung Cancer Cell Lines Displaying a Stem-Like Signature , 2013, PloS one.
[97] A. Borczuk,et al. PARP inhibition selectively increases sensitivity to cisplatin in ERCC1-low non-small cell lung cancer cells. , 2013, Carcinogenesis.
[98] P. Johnston,et al. The role of BRCA1 in the cellular response to chemotherapy. , 2004, Journal of the National Cancer Institute.
[99] Yufei Wang,et al. Role of ERCC1 variants in response to chemotherapy and clinical outcome of advanced non-small cell lung cancer , 2014, Tumor Biology.
[100] Brian H. Dunford-Shore,et al. Somatic mutations affect key pathways in lung adenocarcinoma , 2008, Nature.
[101] David J. Chen,et al. The endless tale of non-homologous end-joining , 2008, Cell Research.
[102] S. Ahmad. Platinum–DNA Interactions and Subsequent Cellular Processes Controlling Sensitivity to Anticancer Platinum Complexes , 2010, Chemistry & biodiversity.
[103] M. F. White,et al. hSSB1 interacts directly with the MRN complex stimulating its recruitment to DNA double-strand breaks and its endo-nuclease activity , 2011, Nucleic acids research.
[104] M. Evans,et al. Poly(ADP-ribose) Polymerase 1 (PARP-1) Binds to 8-Oxoguanine-DNA Glycosylase (OGG1)* , 2011, The Journal of Biological Chemistry.
[105] Enni Markkanen,et al. Oxygen as a friend and enemy: How to combat the mutational potential of 8-oxo-guanine. , 2010, DNA repair.
[106] M. Gatei,et al. Ataxia Telangiectasia Mutated (ATM) Kinase and ATM and Rad3 Related Kinase Mediate Phosphorylation of Brca1 at Distinct and Overlapping Sites , 2001, The Journal of Biological Chemistry.
[107] Y. Bignon,et al. Inhibition of BRCA1 leads to increased chemoresistance to microtubule-interfering agents, an effect that involves the JNK pathway , 2001, Oncogene.
[108] M. Lieber,et al. The Mechanism of Human Nonhomologous DNA End Joining* , 2008, Journal of Biological Chemistry.
[109] M. Evans,et al. Accumulation of Oxidatively Induced DNA Damage in Human Breast Cancer Cell Lines Following Treatment with Hydrogen Peroxide , 2007, Cell cycle.
[110] Eric F. Johnson,et al. ABT-888, an Orally Active Poly(ADP-Ribose) Polymerase Inhibitor that Potentiates DNA-Damaging Agents in Preclinical Tumor Models , 2007, Clinical Cancer Research.
[111] A. Fedier,et al. The effect of loss of Brca1 on the sensitivity to anticancer agents in p53-deficient cells. , 2003, International journal of oncology.
[112] Josef Jiricny,et al. Mediating mismatch repair , 2000, Nature Genetics.
[113] K. Khanna,et al. Involvement of Exo1b in DNA damage-induced apoptosis , 2009, Nucleic acids research.
[114] D. Smeets,et al. Nijmegen Breakage Syndrome: a progress report. , 1994, International journal of radiation biology.
[115] Masato Hareyama,et al. The combination of olaparib and camptothecin for effective radiosensitization , 2012, Radiation oncology.
[116] A. Chen,et al. Molecular Pathways: Targeting PARP in Cancer Treatment , 2012, Clinical Cancer Research.
[117] I. Herskowitz,et al. Uptake of the anticancer drug cisplatin mediated by the copper transporter Ctr1 in yeast and mammals , 2002, Proceedings of the National Academy of Sciences of the United States of America.
[118] C. Redon,et al. Histone H2AX in DNA damage and repair. , 2003, Cancer biology & therapy.
[119] Qi-En Wang,et al. Stem cell protein Piwil2 modulates chromatin modifications upon cisplatin treatment. , 2011, Mutation research.
[120] Y. T. Kim,et al. Proteins involved in DNA damage response pathways and survival of stage I non-small-cell lung cancer patients. , 2012, Annals of oncology : official journal of the European Society for Medical Oncology.
[121] P. Sung. Catalysis of ATP-dependent homologous DNA pairing and strand exchange by yeast RAD51 protein. , 1994, Science.
[122] Sudhir Srivastava,et al. Revised Bethesda Guidelines for hereditary nonpolyposis colorectal cancer (Lynch syndrome) and microsatellite instability. , 2004, Journal of the National Cancer Institute.
[123] Rui-Xi Hua,et al. Associations between polymorphisms of the XPC gene and lung cancer susceptibility: a meta-analysis , 2014, Tumor Biology.
[124] P. Cole,et al. The DNA-Binding Domain of Human PARP-1 Interacts with DNA Single-Strand Breaks as a Monomer through Its Second Zinc Finger , 2011, Journal of molecular biology.
[125] C. Wang,et al. Association of BRCA1 with the hRad50-hMre11-p95 complex and the DNA damage response. , 1999, Science.
[126] J. Nickoloff,et al. Regulation of DNA double-strand break repair pathway choice , 2008, Cell Research.
[127] F. Dick,et al. Chromosome instability and deregulated proliferation: an unavoidable duo , 2012, Cellular and Molecular Life Sciences.
[128] Steven J. M. Jones,et al. Comprehensive genomic characterization of squamous cell lung cancers , 2012, Nature.
[129] K. Khanna,et al. DNA double-strand breaks: signaling, repair and the cancer connection , 2001, Nature Genetics.
[130] Linking environmental carcinogen exposure to TP53 mutations in human tumours using the human TP53 knock‐in (Hupki) mouse model , 2010 .
[131] H. Hsu,et al. Lung cancer susceptibility and prognosis associated with polymorphisms in the nonhomologous end‐joining pathway genes , 2009, Cancer.
[132] T. O'Connor,et al. Enhancement of Synthetic Lethality via Combinations of ABT-888, a PARP Inhibitor, and Carboplatin In Vitro and In Vivo Using BRCA1 and BRCA2 Isogenic Models , 2012, Molecular Cancer Therapeutics.
[133] David J. Chen,et al. hSSB1 rapidly binds at the sites of DNA double-strand breaks and is required for the efficient recruitment of the MRN complex , 2010, Nucleic acids research.
[134] R. Kanaar,et al. Dealing with DNA damage: relationships between checkpoint and repair pathways. , 2010, Mutation research.
[135] Michael Thomas,et al. Crizotinib versus chemotherapy in advanced ALK-positive lung cancer. , 2013, The New England journal of medicine.
[136] F. Guengerich,et al. Common and uncommon cytochrome P450 reactions related to metabolism and chemical toxicity. , 2001, Chemical research in toxicology.
[137] V. O'shea,et al. Base-excision repair of oxidative DNA damage , 2007, Nature.
[138] F. Lin,et al. ATM-Mediated Stabilization of hMutL DNA Mismatch Repair Proteins Augments p53 Activation during DNA Damage , 2004, Molecular and Cellular Biology.
[139] C. Collins,et al. In Brief: Chromothripsis and cancer , 2013, Journal of Pathology.
[140] Li Ding,et al. Genomic Landscape of Non-Small Cell Lung Cancer in Smokers and Never-Smokers , 2012, Cell.
[141] Xiaoye Zhang,et al. Association between the hOGG1 Ser326Cys polymorphism and lung cancer susceptibility: a meta-analysis based on 22,475 subjects , 2013, Diagnostic Pathology.
[142] P. Hainaut,et al. 30 years and a long way into p53 research. , 2009, The Lancet. Oncology.
[143] K. O'Byrne,et al. Human single-stranded DNA binding proteins are essential for maintaining genomic stability , 2013, BMC Molecular Biology.
[144] E. Parlanti,et al. 8-Oxoguanine DNA damage: at the crossroad of alternative repair pathways. , 2003, Mutation research.